NICE Technology Appraisal 184

Topotecan for the treatment of relapsed small-cell lung cancer


  • Oral topotecan is recommended as a possible treatment for people with relapsed small-cell lung cancer if:
    • re-treatment with the first-line regimen is not considered appropriate and
    • there is a medical reason why they cannot take the combination of cyclophosphamide, doxorubicin, and vincristine
  • Intravenous topotecan is not recommended for people with relapsed small-cell lung cancer.
Web address:
NICE Public Health Guidance 22

Promoting mental wellbeing through productive and healthy working conditions: guidance for employers

The recommendations from NICE cover:

  • Adoption of a strategic and coordinated approach to promoting employees’ mental wellbeing
  • Assessing opportunities for promoting wellbeing and managing risks
  • Flexible working
  • The role of line managers.
Web address: